logo-loader

Admedus enters into agreement with SIO Partners for $1 million debt facility

Last updated: 18:40 08 May 2019 AEST, First published: 04:40 08 May 2019 AEST

1557305161_shutterstock_566240770
Admedus is an Australian medical technology company hoping to gain momentum with its ADAPT products aimed at heart surgeons

Admedus Ltd (ASX:AHZ) has entered into a facility agreement with SIO partners LP (SIO) for a secured debt facility of $1 million.

The proceeds of the SIO facility will provide funds for general working capital and operational costs.

The company will continue with the restructure of its business operations to reduce certain overhead costs and a proposed divestment of the infusion business to capitalise on its growing ADAPT business.

READ: Admedus in trading halt pending update on Admedus Immunotherapies transaction

The key terms of the SIO facility are:

  • 18-month term;

  • 12% interest rate compounding monthly; and

  • One-off $125,000 facility fee, which will be capitalised to the loan balance and repayable at maturity.

If Admedus launches a rights issue while the loan is outstanding, SIO may elect to offset all or part of the outstanding balance against its entitlement and any underwriting commitment.

If shareholder approval is obtained, the outstanding balance may at SIO’s election be converted to ordinary shares in AHZ at the lesser of:

  • 2 cents per share; and

  • 80% of the volume weighted average market price for ordinary shares calculated over 5 trading days before the date on which the shares are to be issued.

Anteris talks market superiority of its biomimetic TAVR valve

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive after the successful completion of enrolment for the company’s early feasibility study (EFS) to evaluate DurAVR™ THV. This unique device represents a new class of biomimetic valve and stands as the world's...

on 31/10/23